A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects

• Автори: Yue Fei (Автор), Na Li (Автор), Weilin Qian (Автор), Yang Fan (Автор), Yu Shen (Автор), Quanren Wang (Автор), Kristi McLendon (Автор), Kai Shen (Автор)
• Формат: Книга
• Опубліковано: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

IntroductionThymic stromal lymphopoietin (TSLP) is integral to inducing innate and T helper two cell inflammation that leads to clinical symptoms of asthma. SHR-1905 is a humanized immunoglobulin G1 kappa monoclonal antibody that inhibits TSLP bioactivity, developed for the treatment of severe uncon...